Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(22):1668-1670; doi:10.1093/jnci/94.22.1668
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Baldwin, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baldwin, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 22, 1668-1670, November 20, 2002
© 2002 Oxford University Press

NEWS

Demand Grows for Early Access to Promising Cancer Drugs

Joyce Baldwin

The first 10% of the full text of this article appears below.

In recent years, expanded access programs have allowed thousands of patients with cancer to gain access to investigational drugs before they are approved by the U.S. Food and Drug Administration. Prior to the mid-1990s, patients who had exhausted all standard avenues of treatment were able to obtain investigational drugs only on a case-by-case basis.

Expanded access programs are an extension of more traditional compassionate use programs and allow patients to receive investigational drugs earlier than phase III of the clinical trial process. (See sidebar, p. 1669, for descriptions of various ways patients can gain access to investigational drugs.)

Patient advocacy groups have played a key role in the growth of expanded access programs. Over the last decade, the number of advocacy groups for cancer patients has swelled to several hundred, and members of these groups have become increasingly educated about the intricacies of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
J. Geneve
Re: Demand Grows for Early Access to Promising Cancer Drugs
J Natl Cancer Inst, March 19, 2003; 95(6): 492 - 492.
[Full Text] [PDF]